The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.d

Lupus - Lupus syndrome (see also Vd)

Publications

Arnaud L, Mertz P, Gavand PE, Martin T, Chasset F, Tebacher-Alt M, Lambert A, Muller C, Sibilia J, Lebrun-Vignes B, Salem JE

Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database.

Annals of the rheumatic diseases. 2019;78(4):504-508

Rubin RL

Drug-induced lupus.

Toxicology. 2005;209(2):135-47

KAPLAN JM, WACHTEL HL, CZARNECKI SW, SAMPSON JJ

LUPUS-LIKE ILLNESS PRECIPITATED BY PROCAINAMIDE HYDROCHLORIDE.

JAMA. 1965;192:444-7

LADD AT

Procainamide-induced lupus erythematosus.

The New England journal of medicine. 1962;267:1357-8

London BL, Pincus I

Reversible lupus-like illness induced by procainamide.

American heart journal. 1966;72(6):806-8

Blomgren SE, Condemi JJ, Bignall MC, Vaughan JH

Antinuclear antibody induced by procainamide. A prospective study.

The New England journal of medicine. 1969;281(2):64-6

Rubin RL, Nusinow SR, Johnson AD, Rubenson DS, Curd JG, Tan EM

Serologic changes during induction of lupus-like disease by procainamide.

The American journal of medicine. 1986;80(5):999-1002

Mongey AB, Donovan-Brand R, Thomas TJ, Adams LE, Hess EV

Serologic evaluation of patients receiving procainamide.

Arthritis and rheumatism. 1992;35(2):219-23